269 related articles for article (PubMed ID: 33457225)
1. Systematic sampling during MRI-US fusion prostate biopsy can overcome errors of targeting-prospective single center experience after 300 cases in first biopsy setting.
Cata E; Andras I; Ferro M; Kadula P; Leucuta D; Musi G; Matei DV; De Cobelli O; Tamas-Szora A; Caraiani C; Lebovici A; Epure F; Bungardean M; Coman RT; Crisan N
Transl Androl Urol; 2020 Dec; 9(6):2510-2518. PubMed ID: 33457225
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
3. MRI-TRUS fusion guided prostate biopsy - initial experience and assessment of the role of contralateral lobe systematic biopsy.
Andras I; Crisan D; Cata E; Tamas-Szora A; Caraiani C; Coman RT; Bungardean C; Mirescu C; Coman I; Crisan N
Med Ultrason; 2019 Feb; 21(1):37-44. PubMed ID: 30779829
[TBL] [Abstract][Full Text] [Related]
4. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
5. The value of magnetic resonance imaging-ultrasound fusion targeted biopsies for clinical decision-making among patients with previously negative transrectal ultrasound biopsy and persistent prostate-specific antigen elevation.
Gillis CJ; Southall TM; Wilson R; Anderson M; Young J; Hewitt R; Andrews M
Can Urol Assoc J; 2022 Jun; 16(6):E315-E320. PubMed ID: 35099383
[TBL] [Abstract][Full Text] [Related]
6. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
7. Performance of standard systematic biopsy versus MRI/TRUS fusion biopsy using the Navigo® system in contemporary cohort.
Nativ O; Shefler A; Bejar J; Peschansky S; Lavi A; Michael C; Nativ O
Urol Oncol; 2024 May; 42(5):159.e1-159.e7. PubMed ID: 38431487
[TBL] [Abstract][Full Text] [Related]
8. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
9. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
10. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
Dell'Oglio P; Stabile A; Soligo M; Brembilla G; Esposito A; Gandaglia G; Fossati N; Bravi CA; Dehò F; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973
[TBL] [Abstract][Full Text] [Related]
11. The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.
Zhang X; Hong H; Liang D
Cancer Imaging; 2022 Oct; 22(1):60. PubMed ID: 36258247
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
13. The accuracy of prostate cancer diagnosis in biopsy-naive patients using combined magnetic resonance imaging and transrectal ultrasound fusion-targeted prostate biopsy.
Uno H; Taniguchi T; Seike K; Kato D; Takai M; Iinuma K; Horie K; Nakane K; Koie T
Transl Androl Urol; 2021 Jul; 10(7):2982-2989. PubMed ID: 34430401
[TBL] [Abstract][Full Text] [Related]
14. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
[TBL] [Abstract][Full Text] [Related]
15. A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis.
Wang X; Xie Y; Zheng X; Liu B; Chen H; Li J; Ma X; Xiang J; Weng G; Zhu W; Wang G; Fang Y; Cheng H; Xie L
World J Urol; 2023 Mar; 41(3):653-662. PubMed ID: 35852595
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging-targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer.
Alkema NG; Hoogeveen SFJS; Cauberg ECC; Witte LPW; van 't Veer-Ten Kate M; de Boer E; Hoogland MAM; Blanker MH; Boomsma MF; Steffens MG
Eur Urol Open Sci; 2022 Oct; 44():125-130. PubMed ID: 36185584
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy.
Baco E; Rud E; Eri LM; Moen G; Vlatkovic L; Svindland A; Eggesbø HB; Ukimura O
Eur Urol; 2016 Jan; 69(1):149-56. PubMed ID: 25862143
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
20. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.
Volkin D; Turkbey B; Hoang AN; Rais-Bahrami S; Yerram N; Walton-Diaz A; Nix JW; Wood BJ; Choyke PL; Pinto PA
BJU Int; 2014 Dec; 114(6b):E43-E49. PubMed ID: 24712649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
